Jun 28, 2026
The global insulin drugs and delivery devices market is dominated by three manufacturers supplying roughly 90% of volume, with biosimilar entry slowly eroding this oligopoly. The market is projected to see continued growth driven by rising diabetes prevalence, while pricing pressure from biosimilars and government policies accelerates. In the Middle East, the recombinant human insulin market is projected to expand at a 6–8% CAGR through 2035.
Jun 19, 2026
AstraZeneca is advancing its oral GLP-1 drug into Phase III trials while defending dapagliflozin patents in Australia. The company obtained an Australian court injunction against a generic competitor and has partnered with Evinova to use AI for clinical trials. India could be a future market for the oral GLP-1 drug pending global trial data.
Jun 15, 2026
At the ADA Scientific Sessions, Novo Nordisk's Wegovy pill surpassed 3 million prescriptions within five months, while Structure Therapeutics and AstraZeneca shared mid-stage GLP-1 data targeting a 2029 launch. The US FDA approved TRUQAP as the first targeted treatment for PTEN-deficient metastatic prostate cancer, reducing disease progression risk by 19% in the CAPItello-281 trial. Meanwhile, two major genomic atlas projects—a 4,098-genome infant gut bacteria catalog and Basecamp Research's Trillion Gene Atlas—aim to advance precision probiotics and AI-driven drug discovery, respectively.
Jun 13, 2026
The Delhi High Court ruled Dr. Reddy's can export semaglutide, finding Novo Nordisk's patent unenforceable. Dr. Reddy's plans to launch generic Wegovy at 60% discount pending approval.
Jun 02, 2026
The life sciences industry expects strong growth in 2026 driven by AI adoption and GLP-1 drug innovations, but faces headwinds from tariffs, FDA changes, and rising shareholder activism. Over 320 public activist campaigns have targeted life sciences companies since 2020, with 75-80% of biotech and pharma targets being pre-revenue firms.
May 18, 2026
Wegovy and Mounjaro prices in South Korea are higher than in China and Japan. South Korea added both drugs to a non-insurance reporting system, but immediate price cuts are unlikely.
May 12, 2026
Trump secured agreements with 16 pharmaceutical companies tied to TrumpRx.gov, including most-favoured-nation pricing and direct-to-patient discounts. Several companies disclosed price cuts for obesity, diabetes, insulin and other medicines.
May 10, 2026
Insulin list prices rose more than 300% over two decades as PBMs face growing scrutiny over rebates, spread pricing, and transparency. Reform efforts and pharmacist involvement are central to drug affordability and access.
May 02, 2026
Vermont insurers and employers are scaling back GLP-1 coverage as costs rise, leaving some patients without access. The drugs remain in high demand as studies point to benefits beyond weight loss.
Apr 28, 2026
A Johns Hopkins study found GLP-1 users face increased dementia risk after a decade, possibly due to longer lifespan. A separate JCI review found GLP-1 drugs show neuroprotective signals in preclinical studies but consistent cognitive benefits in humans remain unproven.
Apr 25, 2026
Generic semaglutide launched in India as Novo Nordisk’s patent expired, with prices starting below Rs 1,300 a month. Doctors and companies said device quality, cold chains and patient support will also shape sales.
Apr 22, 2026
AI is reshaping pharma work by adding roles in drug discovery, commercial analytics and in-house AI teams rather than driving major job losses. Companies are also moving toward always-on intelligence as faster market shifts expose the limits of siloed, episodic insight models.
Apr 18, 2026
GLP-1 drugs are expanding in 2026 with oral semaglutide for weight management, rising patient use and broader commercialization. A study also found a modest increase in erectile dysfunction risk among men with Type 2 diabetes starting GLP-1 medicines, though the association weakened after stricter adjustment.
Apr 07, 2026
Biopharma companies are increasingly outsourcing FDA-approved drug manufacturing to Europe despite 15% U.S. tariffs, with Europe recording triple the U.S. deal volume in 2025. Simultaneously, nearly half of pharma companies offshored R&D activities last year, citing talent access and lower costs. Major investments by companies like Novo Nordisk, Eli Lilly, and AstraZeneca highlight the ongoing shift of pharmaceutical operations overseas.
Apr 07, 2026
Boots has launched an in-store weight loss service across 17 UK locations, offering face-to-face consultations for weight-loss injections like Wegovy and Mounjaro. The service includes a 10-week free weight loss programme and 12-month aftercare, with prices starting at £99.97 for Wegovy. This marks the first high street pharmacy to provide such in-person weight loss treatment consultations.
Apr 06, 2026
Big drug companies said Trump administration pricing deals had little to no noticeable impact on earnings, though details remain confidential. Novo Nordisk and Eli Lilly described bigger effects tied to lower GLP-1 cash-pay prices and expanded Medicare coverage.
Apr 06, 2026
Doctors said Americans starting obesity treatment are showing interest in oral GLP-1 drugs because of lower cost and convenience. Novo’s oral Wegovy and Lilly’s Foundayo are priced below injectable options.
Apr 06, 2026
Soon-to-be brides and grooms in India are increasingly seeking Mounjaro and other weight-loss injections before weddings, with doctors reporting rising demand. The trend comes as India’s obesity-drug market expands, cheaper semaglutide versions enter the market, and regulators raise misuse concerns.
Apr 03, 2026
President Trump imposes 100% tariffs on imported branded drugs from companies refusing price cuts or U.S. production moves. Sixteen major pharmaceutical firms have secured tariff exemptions by agreeing to align U.S. prices with other developed nations and invest in domestic manufacturing. The policy aims to reduce prescription drug costs and rebuild domestic pharmaceutical production capacity.
Apr 01, 2026
The FDA has shifted from regulatory ambiguity to coordinated enforcement against compounded oral semaglutide, culminating in a 2026 announcement of intent to take action against non-approved GLP-1 drugs. Hims & Hers Health's 2024 oral semaglutide offering marked the beginning of a broader regulatory reckoning that saw manufacturer pressure, formal shortage declarations, and warning letters targeting compounding practices.
